首页>投融资
OncoResponse
未透露
OncoResponse is an immuno-oncology antibody discovery company, launched jointly by the MD Anderson Cancer Center and Theraclone Sciences to identify therapeutic antibodies against novel targets from immuno-oncology using Theraclone's I-STAR immune repertoire screening technology.In May 2023, OncoResponse awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas.In February 2022, Oxford Finance LLC announced the closing of a $50 million senior secured term loan with OncoResponse.In March 2021, OncoResponse announced that it has raised $40.6 million in a Series C financing.In September 2018, the company closed a $40 million Series B financing round.In March 2017, the company closed a $22.5 million Series A financing round.In October 2016, the company raised $7 million in a supplemental Series A financing that consisted of a $3.5 million investment from GreatPoint Ventures and a $3.5 million investment from the Helsinn Investment
基本信息
-
公司全称OncoResponse Inc
-
类型癌症免疫治疗研发商
-
产业领域药品研发/制造、医药研发/制造、生物药
-
公司人数15~50人
-
地址1124 Columbia Street Suite 300 SEATTLE WASHINGTON 98104; US; Telephone: +12068051600; Fax: +12068051699;
-
联系电话206-805-1600
-
邮箱info@oncoresponseinc.com
-
成立时间2015-01-01
投融资
-
2023-05-18未透露1400万美元Canaan PartnersARCH Venture PartnersTakeda VenturesBering CapitalInterVestRiverVest3B Future Health Fund
-
2021-03-31C轮4060万美元Canaan PartnersARCH Venture PartnersQatar Investment AuthorityRedmile GroupYonjin VentureBering CapitalRiverVestMagnetar Group3B Future Health Fund
-
2018-09-11B轮4000万美元Alexandria Venture InvestmentsCanaan PartnersARCH Venture PartnersWilliam Marsh Rice UniversityQatar Investment AuthorityRedmile GroupHT Family OfficeHelsinn Investment FundRiverVest
-
2017-03-10A轮2250万美元ARCH Venture PartnersCanaan PartnersHT Family OfficeAlexandria Venture Investments
-
2016-10-10A轮700万美元Helsinn Investment FundGreatPoint VenturesAlexandria Venture Investments
-
2016-05-27A轮1250万美元Baxalta Ventures
- 加载更多
相关投融资企业
收并购
位于美国的Aliada Therapeutics Inc是一家专注于生物医药研发的公司。他们致力于通过创新的治疗方法，为患者提供更有效的医疗方案。公司主要研究方向包括基因疗法和细胞疗法，旨在治疗一些目前尚无有效治愈方法的疾病。Aliada Therapeutics Inc拥有一支专业的研发团队，并与多家知名医疗机构合作，共同推动医疗科技的发展。
B轮
Citryll正在采取一种新的方法来治疗自身免疫和其他人类疾病，例如狼疮、血管炎、肺纤维化、类风湿性关节炎和败血症引起的器官损害，其方法是靶向并抑制自身抗原和中性粒细胞外诱捕剂（NET）衍生的毒性源分子而不是广泛针对炎症或获得性免疫。后者是当前药物的MoAs，例如抗TNF抗体、小分子Jak抑制剂和B细胞生物学拮抗剂（例如抗CD20抗体）。
B轮
Nuvig Therapeutics 是一家以科学为导向的临床研究开发组织，专注于将新的科学见解转化为炎症和自身免疫性疾病患者的治疗方法。我们不依赖于传统的免疫抑制机制，而是专注于通过治疗诱导免疫稳态的自然机制来调节免疫功能。我们的管道将扩展到专门针对不同自身免疫适应症的产品平台。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息